
Chiesi, a biopharma group focused on treating respiratory diseases, has inaugurated an expansion of its manufacturing and industrial site in …

French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

